{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:33:02Z","timestamp":1793316782351,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium fur Bildung und Forschung Dienststelle Bonn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaci.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:29:04Z","timestamp":1789860544000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-033X","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Krausz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Sogkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Uhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigune","family":"Goldacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Fei\u00dft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Warnatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Grimbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.09.007_bib1","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2016-04-712612","article-title":"CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency","volume":"128","author":"Lo","year":"2016","journal-title":"Blood"},{"issue":"6246","key":"10.1016\/j.jaci.2026.09.007_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.09.007_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4049\/jimmunol.159.1.144","article-title":"Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression","volume":"159","author":"Chuang","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib4","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.4049\/jimmunol.174.8.4803","article-title":"Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells","volume":"174","author":"Mead","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib5","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"issue":"6204","key":"10.1016\/j.jaci.2026.09.007_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaci.2026.09.007_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood.2019000929","article-title":"Current genetic landscape in common variable immune deficiency","volume":"135","author":"Abolhassani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.09.007_bib8","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4\u2013insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib9","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3389\/fimmu.2018.02012","article-title":"Increased risk for malignancies in 131 affected CTLA4 mutation carriers","volume":"9","author":"Egg","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2021013496","article-title":"Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects","volume":"139","author":"Dhunputh","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.09.007_bib12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2016-10-745174","article-title":"Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations","volume":"129","author":"Hou","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.09.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.101008","article-title":"The ABACHAI clinical trial protocol: safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: a non controlled phase 2 clinical trial","volume":"30","author":"Krausz","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.jaci.2026.09.007_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3899\/jrheum.130112","article-title":"Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2026.09.007_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-023-03067-x","article-title":"Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries","volume":"25","author":"Dominique","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2026.09.007_bib16","first-page":"21","article-title":"Der deutsche SF-36 Health Survey \u00dcbersetzung und psychometrische Testung eines krankheits\u00fcbergreifenden Instruments zur Erfassung der gesundheitsbezogenen Lebensqualit\u00e4t","volume":"3","author":"Bullinger","year":"1995","journal-title":"Z F\u00fcr Gesundheitswissenschaften J Public Health"},{"key":"10.1016\/j.jaci.2026.09.007_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/s-2004-812835","article-title":"Validation of the inflammatory bowel disease questionnaire IBDQ-D, German version, for patients with ileal pouch anal anastomosis for ulcerative colitis","volume":"42","author":"H\u00e4user","year":"2004","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jaci.2026.09.007_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1055\/s-2005-858579","article-title":"Lebensqualit\u00e4t bei chronisch entz\u00fcndlichen Darmerkrankungen (CED): die deutsche Version des Inflammatory Bowel Disease Questionnaire (IBDQ-D) zur krankheitsspezifischen Lebensqualit\u00e4tsmessung\u2014erste Anwendung und Vergleich mit anderen internationalen Fas","volume":"67","author":"Janke","year":"2005","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.jaci.2026.09.007_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-2006-932661","article-title":"Validierung der Deutschen Version (Kompetenznetz \u201cChronisch entz\u00fcndliche Darmerkrankungen\u201d) des inflammatory bowel disease questionnaire IBDQ-D TT\u2014validation of the German version of the inflammatory bowel disease questionnaire (Competence Network IBD)","volume":"56","author":"Janke","year":"2006","journal-title":"Psychother Psych Med"},{"key":"10.1016\/j.jaci.2026.09.007_bib20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2026.09.007_bib21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.aje.a115507","article-title":"A simple method to calculate the confidence interval of a standardized mortality ratio (SMR)","volume":"131","author":"Ulm","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jaci.2026.09.007_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786516","article-title":"Establishing the molecular diagnoses in a cohort of 291 patients with predominantly antibody deficiency by targeted next-generation sequencing: experience from a monocentric study","volume":"12","author":"Rojas-Restrepo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1011646","article-title":"Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?","volume":"13","author":"Krausz","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12882-022-02999-x","article-title":"Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report","volume":"23","author":"Kohatsu","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jaci.2026.09.007_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.662645","article-title":"Different apples, same tree: visualizing current biological and clinical insights into CTLA-4 insufficiency and LRBA and DEF6 deficiencies","author":"G\u00e1mez-D\u00edaz","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2026.09.007_bib26","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jaci.2023.08.004","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","volume":"152","author":"Taghizade","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib27","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaci.2024.08.020","article-title":"Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: a European Society for Blood and Marrow Transplantation Inborn Errors Working Party study","volume":"154","author":"Tsilifis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.09.007_bib28","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.1182\/bloodadvances.2023010105","article-title":"Management and outcome of COVID-19 in CTLA-4 insufficiency","volume":"7","author":"Ochoa","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2026.09.007_bib29","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaci.2026.09.007_bib30","first-page":"377","article-title":"Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series","volume":"42","author":"Xia","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2026.09.007_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaip.2020.10.028","article-title":"Abatacept use is associated with steroid dose reduction and improvement in fatigue and CD4-dysregulation in CVID patients with interstitial lung disease","volume":"9","author":"Von Spee-Mayer","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.09.007_bib32","doi-asserted-by":"crossref","first-page":"e1560","DOI":"10.1212\/WNL.0000000000207609","article-title":"Clinical, radiologic, and immunologic features of patients with CTLA4 deficiency with neurologic involvement","volume":"101","author":"Coustal","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.jaci.2026.09.007_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/hematology.2020000153","article-title":"Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)","volume":"2020","author":"Seidel","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.jaci.2026.09.007_bib34","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1\u2013risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jaci.2026.09.007_bib35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/bjh.14792","article-title":"Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy","volume":"178","author":"Fenaux","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2026.09.007_bib36","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:57:20Z","timestamp":1793314640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926006445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S0091674926006445"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.09.007","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABACHAI phase 2 clinical trial: Safety and efficacy of subcutaneous abatacept in patients with CTLA-4 insufficiency or LRBA deficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}